NCT06714942 Efficacy and Safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women With High Stress and Anxiety: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
| NCT ID | NCT06714942 |
| Status | Recruiting |
| Phase | — |
| Sponsor | SF Research Institute, Inc. |
| Condition | Stress |
| Study Type | INTERVENTIONAL |
| Enrollment | 51 participants |
| Start Date | 2024-10-25 |
| Primary Completion | 2024-12-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 51 participants in total. It began in 2024-10-25 with a primary completion date of 2024-12-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women with High Stress and Anxiety. All eligible subjects who meet the Inclusion and Exclusion criteria will be part of the study. Subjects will be informed about the purpose of the study and signed informed consent will be taken. Subjects will be randomized to either one of the three treatment arms. Subjects will then be asked to either take one capsule containing the proprietary blend of Ashwagandha root extract or Ashwagandha root extract or Placebo orally twice daily with a glass of water for 8 weeks. The primary objective is to compare the efficacy of a proprietary blend of Ashwagandha root extract in adults experiencing stress and anxiety. The secondary objective is to compare the safety of a proprietary blend versus KSM-66 versus Placebo in adults experiencing stress and anxiety.
Eligibility Criteria
Inclusion Criteria: 1. Adults (male and female) aged between 18 and 65 years. 2. Experiencing signs and symptoms suggestive of stress (e.g., difficulty, concentrating, physical exhaustion, anxiety, restlessness, insomnia, headache, fatigue, loss of appetite, worry, sweating, mental confusion, etc.). 3. Hamilton Anxiety Rating Scale (HAM-A) total score between 14 and 30 at the screening/randomization visit. 4. Perceived Stress Scale (PSS) score ≥13 at the screening/randomization visit. 5. BMI between 20 and 35. 6. No plan to commence new treatments over the study period. 7. Medication-free (any medications are known to affect stress and anxiety) for at least 4 weeks. Use of analgesics (once a week) or contraceptive pills are permissible. 8. Must have the ability and willingness to sign an informed consent and to comply with all study procedures. Exclusion Criteria: 1. Patients receiving any of the medications known to affect stress and anxiety (corticosteroids, antidepressants, antipsychotics, mood stabilizers, and anti-epileptic medications) during 4 weeks prior to screening. 2. Patients having a total score of less than 14 on HAM-A at screening. 3. Patients currently (or within the past 4 weeks prior to screening) taking any over-the-counter use of herbal extracts such as Ginkgo Biloba, St. John's Wort, Omega-3, etc. 4. Patients with a depressive episode, suicidal tendency, panic disorder, social phobia, obsessive-compulsory disorder; alcohol dependency; schizophrenia, and mania. 5. Patients with known post-traumatic stress disorder (PTSD) and Generalized Anxiety Disorder (GAD). 6. Patients who have an established practice of meditation and relaxation techniques for three or more months. 7. Patients with known clinically significant acute unstable hepatic, renal, cardiovascular, or respiratory disease that will prevent participation in the study. 8. Patients with a history of alcohol, tobacco dependence, or any substance abuse. 9. Pregnant and lactating women or suspected to be pregnant. 10. Patients with known hypersensitivity to Ashwagandha. 11. Patients who had participated in other clinical trials during the previous 3 months. 12. Patients who have any clinical condition, according to the investigator who does not allow safe fulfilment of clinical trial protocol.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06714942 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Stress. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06714942 currently recruiting?
Yes, NCT06714942 is actively recruiting participants. Contact the research team at jademola@sfinstitute.com for enrollment information.
Where is the NCT06714942 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06714942 clinical trial?
NCT06714942 is sponsored by SF Research Institute, Inc.. The trial plans to enroll 51 participants.